This coherent mathematical and statistical approach aimed at graduate students incorporates regression and topology as well as graph theory.

Nearly 20 million nuclear medicine procedures are carried out each year in the United States alone to diagnose and treat cancers, cardiovascular disease, and certain neurological disorders. Many of the advancements in nuclear medicine have been the result of research investments made during the past 50 years where these procedures are now a routine part of clinical care. Although nuclear medicine plays an important role in biomedical research and disease management, its promise is only beginning to be realized. Advancing Nuclear Medicine Through Innovation highlights the exciting emerging opportunities in nuclear medicine, which include assessing the efficacy of new drugs in development, individualizing treatment to the patient, and understanding the biology of human diseases. Health care and pharmaceutical professionals will be most interested in this book's examination of the challenges the field faces and its recommendations for ways to reduce these impediments.

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

This book introduces undergraduate, postgraduate and research students and scientists to animal models of neurological disorders, along with their working principle and brief procedures. Addressing all the disorders related to the central nervous system (CNS) in a single platform, on the basis of various literature surveys it describes different procedures to induce a single disease with the help of toxins/chemicals. It also includes numerous protocols for inducing single neurological diseases, thus fulfilling an urgent need for a book that makes specific procedures for neurological disorders available, so that specific disease can be induced in laboratories according to the availability of resources. Further, it acquaints readers with the pathological changes that occur in a particular neurological disorder, which reflect specific signs and symptoms of any particular disease, and examines how they affect everyday life. It is a valuable resource for researchers aiming to eradicate or improve neurological disorders by testing the benefits of different drugs.

This textbook is a practical guide to the use of small animal imaging in preclinical research that will assist in the choice of imaging modality and contrast agent and in study design, experimental setup, and data evaluation. All established imaging modalities are discussed in detail, with the assistance of numerous informative illustrations. While the focus of the new edition remains on practical basics, it has been updated to encompass a variety of emerging imaging modalities, methods, and applications. Additional useful hints are also supplied on the installation of a small animal unit, study planning, animal handling, and cost-effective performance of small animal imaging. Cross-calibration methods and data postprocessing are considered in depth. This new edition of Small Animal Imaging will be an invaluable aid for researchers, students, and technicians involved in research into and applications of small animal imaging.

This book, now in a fully updated second edition, is a comprehensive and up-to-date guide to the use of PET and SPECT for the imaging of neurobiological systems. Diverse aspects of neurotransmission in the brain are discussed, such as visualization and quantification of neuroreceptors, neuroinflammatory markers, transporters, and enzymes as well as neurotransmitter synthesis, β-amyloid deposition, cerebral blood flow, and the metabolic rate of glucose. The latest results in probe development are also detailed. A wide range of systems not addressed in the first edition are covered, reflecting the advances made in recent years. The book combines the expertise of authors internationally renowned for their dedication to the development of novel probes and techniques for the investigation of neurobiological systems. Most chapters are written jointly by radiochemists and nuclear medicine specialists to ensure a multidisciplinary approach. This state of the art compendium will be valuable to all with an interest in clinical and preclinical neuroscience. Companion volumes on the use of PET and SPECT in neurology and psychiatry complete a trilogy.

The proposed book will act as a guide for scientists and clinicians to the unique information that MRS can provide. It will be a comprehensive overview of clinical and pre-clinical MRS applications and potential clinical utility of MRS biomarkers in degenerative brain diseases from leading experts in the field. MRS has proven to be a powerful complementary tool to MRI for the diagnosis and monitoring of disease progression and response to treatment because it can detect changes in cell density, cell type, and biochemical composition, not just structural changes. As the population in the developed world continues to age, neuroimaging for diagnosis, prognosis, and therapy monitoring of neurodegenerative diseases becomes increasingly important and there has been a recent surge of clinical and pre-clinical applications of MRS indicating that this technique can provide robust and non-invasive biomarkers of degeneration. ​

Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies.